The Protein Myth: Our Obsession With Protein and How It Is Killing US

Houston Methodist

G. Davis

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Medications for Weight Loss: The New Satiety Hormones

Scripps Health

K. Fujioka

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Tirzepatide Updates

Diana Isaacs

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg

Weightloss in Menopause

Susan Brian

Exercise, Weight Loss, and Breast Cancer Risk: The Importance of BMI

Cleveland Clinic Taussig Cancer Institute

A. Guthrie

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Tirzepatide for Type 2 Diabetes

Diana Isaacs

Obesity: New Understanding and Treatments

Norman Lepor

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian